Federal prosecutors are seeking roughly $1 billion to resolve a long-running probe into Johnson & Johnson’s marketing of the antipsychotic drug Risperdal, according to people familiar with the matter. A settlement of around $1 billion would be among the largest in a string of settlements related to off-label marketing of drugs in recent years, and would likely have a material impact on J&J’s quarterly financial results.
